Research and Markets: Commercializing the Stem Cell Sciences

<0> Research and Markets: Commercializing the Stem Cell Sciences </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of Woodhead Publishing Ltd's new book "Commercializing the stem cell sciences" to their offering.

Commercializing the Stem Cell Sciences offers a comparative analysis of the commercial methods adopted in the global stem cell industries, and seeks to establish whether there is an optimum commercial model, and to examine what emerging companies can learn from their predecessors. Following an introduction to stem cell sciences and the problems involved in their commercialization, the book begins with a discussion of stem cell treatments from a global perspective, and the role of innovation in the commercialization of biotechnology in general. In the second half of the book, chapters focus on the different strategies that can be employed and their relative risks and values, before a conclusion that looks at potential new developments in the field.

- Introduction: Stem cell science, biotechnology and the problem of commercialization

- Stem cell treatments in a global marketplace

- The role of innovation systems in the commercialization of biotechnology

- Low-risk, low value strategies: Adult stem cells

- High-risk, high-value: embryonic stem cells

- Low-risk, low-value: iPS cells

- Conclusion: What will happen next?


Source: Woodhead Publishing Ltd

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.